Skip Navigation LinksHome > October 15, 2013 - Volume 38 - Issue 22S > Clinical Evaluation of a Neuroprotective Drug in Patients Wi...
Spine:
doi: 10.1097/BRS.0b013e3182a7e9b0
Role of Non-Surgical Management in Cervical Spondylotic Myelopathy

Clinical Evaluation of a Neuroprotective Drug in Patients With Cervical Spondylotic Myelopathy Undergoing Surgical Treatment: Design and Rationale for the CSM-Protect Trial

Fehlings, Michael G. MD, PhD, FRCS, FACS*; Wilson, Jefferson R. MD*; Karadimas, Spyridon K. MD*; Arnold, Paul M. MD; Kopjar, Branko MD, MS, PhD

Collapse Box

Abstract

Study Design. Descriptive article and narrative review.

Objective. To explain the rationale and design of the cervical spondylotic myelopathy (CSM)-Protect clinical trial that aims to elucidate the efficacy and safety of riluzole in the context of CSM.

Summary of Background Data. CSM is the most common cause of spinal cord–related dysfunction internationally. Although surgery is effective in preventing the progression of impairment, and in some cases improving functional outcomes, many patients continue to exhibit significant disability in the postoperative setting. Evidence from preclinical studies suggests that glutamate-related excitotoxicity may contribute to the pathology of CSM and that administration of the sodium and glutamate-blocking medication riluzole, when combined with spinal cord decompression, may mitigate this effect and improve neurobehavioral outcomes. Although riluzole is FDA approved and has been shown to be safe and effective in the context of amyotrophic lateral sclerosis, its efficacy and safety in the context of CSM remain unknown.

Methods. Descriptive article with narrative review of the literature.

Results. In addition to providing pertinent preclinical background on the topic, this descriptive article and narrative review discusses the design and current status of an ongoing phase III randomized controlled trial evaluating the efficacy and safety of riluzole, combined with surgical decompression, in the treatment of CSM.

Conclusion. On the basis of current projections, we estimate that the interim analysis for this study will take place in the spring of 2014, at which time an adaptive sample size adjustment may take place.

© 2013 by Lippincott Williams & Wilkins

Follow Us!

  

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.